Stable SIN Lentiviral Vector Integration via AAV ITR Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for integrating Self-Inactivating (SIN) lentiviral transfer vectors into packaging cell lines are complex and inefficient, particularly due to the inactivating deletion in the 3' Long Terminal Repeat (LTR) that makes traditional viral transduction incompatible with the integration of functional transfer vectors, necessitating the development of simpler and more effective integration strategies for stable producer cell line production.
Innovation Solution
A system involving the transfection of DNA fragments containing Inverted Terminal Repeats (ITR) of Adeno-Associated Virus (AAV) at the 5' and 3' flanking a complex construct with a SIN transfer vector and an antibiotic resistance gene, positioned downstream of the lentiviral 3' LTR, allows for stable integration into packaging cell lines containing structural and regulatory lentiviral components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional viral transduction is used to integrate transfer vectors into packaging cell lines, then integration efficiency is high, but the inactivating deletion in the 3' LTR makes the transfer vector incompatible with integration
Solution Approach 1:
The patent uses AAV ITR sequences as an intermediary element to enable stable integration of SIN transfer vectors into packaging cell lines. The AAV ITR sequences flanking the transfer vector allow integration through a non-retroviral mechanism, bypassing the incompatibility caused by the inactivating deletion in the 3' LTR while maintaining the SIN structure
2Reliability
If conditional SIN transfer vectors with inducible promoters are used, then integration compatibility is improved, but the LTR retains basal level expression which compromises vector design
Solution Approach 1:
The patent extracts the problematic basal expression issue by using AAV ITR-mediated integration instead of relying on modified LTR promoters. This approach completely removes the need for inducible promoter systems while achieving stable integration, thereby eliminating the compromise of retained basal LTR expression
3Reliability
If cotransfection of vector plasmid and selectable drug resistance plasmid is used, then integration can be achieved, but both integration efficiency and stability are low
Solution Approach 1:
The patent merges the transfer vector and drug resistance gene into a single integrated construct flanked by AAV ITR sequences. This unified approach ensures that both the transfer vector and selectable marker are co-integrated at the same locus, significantly improving both integration efficiency and stability compared to separate plasmid cotransfection
4Reliability
If concatemeric array transfection is used to integrate fully SIN transfer vectors, then stable producer cell lines can be obtained, but the array formation step adds complexity to the technology
Solution Approach 1:
The patent extracts and eliminates the complex array formation step by using a single linear DNA fragment containing the SIN transfer vector flanked by AAV ITR sequences. This fragment can be directly transfected and integrated into the packaging cell line without requiring concatemeric array construction, thereby simplifying the overall process while maintaining stable producer cell line generation
Data Source
Figure 1a~1c
Figure 2a~2d
Figure 3a~3d
AI summary
The present invention relates to the field of the production of lentiviral vectors (LV) for gene therapy. More particularly, the invention relates to a system to obtain the stable integration of a Self Inactivating (SIN) lentiviral transfer vector into a packaging cell line. The SIN lentiviral transfer vector is integrated using a DNA fragment containing the Inverted Terminal Repeats (ITR) of Adeno Associated Virus (AAV), thus obtaining the stable producer cell line for SIN lentiviral vectors.